Compare MAMA & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | BNTC |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.8M | 405.7M |
| IPO Year | N/A | N/A |
| Metric | MAMA | BNTC |
|---|---|---|
| Price | $13.46 | $12.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $17.00 | ★ $28.25 |
| AVG Volume (30 Days) | ★ 499.5K | 235.3K |
| Earning Date | 12-08-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.91 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $151,312,000.00 | N/A |
| Revenue This Year | $35.43 | N/A |
| Revenue Next Year | $28.82 | N/A |
| P/E Ratio | $111.49 | ★ N/A |
| Revenue Growth | ★ 29.92 | N/A |
| 52 Week Low | $5.50 | $9.70 |
| 52 Week High | $14.50 | $17.15 |
| Indicator | MAMA | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 68.14 | 41.43 |
| Support Level | $11.04 | $12.78 |
| Resistance Level | $14.50 | $13.68 |
| Average True Range (ATR) | 0.74 | 0.75 |
| MACD | 0.23 | 0.00 |
| Stochastic Oscillator | 74.23 | 33.64 |
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.